StockNews.AI
BDMD
StockNews.AI
162 days

Baird Medical Secures Indonesian Regulatory Approval for Microwave Ablation Technology

1. BDMD received regulatory approval in Indonesia for its microwave ablation devices. 2. Approval will enhance BDMD's distribution in emerging markets like Indonesia. 3. The company's technologies improve patient outcomes with minimally invasive procedures. 4. BDMD plans collaboration with Indonesian healthcare providers. 5. Microwave ablation is effective for treating thyroid nodules and tumors.

10m saved
Insight
Article

FAQ

Why Bullish?

Regulatory approval supports BDMD's expansion strategy, likely boosting investor confidence. Historical examples show that companies gaining market approvals often see positive stock movements shortly after news release.

How important is it?

The approval is a significant milestone in BDMD's strategic expansion, suggesting high potential for revenue growth and a positive shift in market perception.

Why Short Term?

The immediate expansion into a new market can yield short-term revenue boosts. Similar scenarios within the medical device sector often reveal increased operational activity follow such announcements.

Related Companies

ISRGSYKZBH
, /PRNewswire/ -- Baird Medical Investment Holdings Ltd. (NASDAQ: BDMD) ("Baird Medical" or the "Company"), a forward-thinking medical device company specializing in AI-powered surgical robotics and next-generation surgical instruments, and a global leader in microwave ablation (MWA) technology, has received regulatory approval from the Indonesian Ministry of Health (Kementerian Kesehatan Republik Indonesia). This approval includes the Great Wall Microwave Therapeutic Instrument and the Great Wall Disposable Microwave Ablation Needle, laying the foundation for Baird Medical to introduce its advanced minimally invasive treatment solutions across Indonesia. Baird Indonesian Certificate "This regulatory approval marks a significant step in our global strategic expansion and underscores our commitment to improving patient care with cutting-edge, minimally invasive technologies," said Haimei Wu, Chairwoman of Baird Medical.  "We look forward to collaborating with Indonesian healthcare providers and supporting them with innovative solutions that enhance precision, safety, and patient outcomes. Microwave ablation is a highly effective, minimally invasive procedure that uses targeted microwave energy to destroy abnormal tissue with minimal impact on surrounding areas. Recognized for its precision and faster recovery times, MWA is widely used for treating conditions such as thyroid nodules and tumors. With this regulatory milestone, Baird Medical is set to expand its distribution network and collaborate with key medical institutions in Indonesia, reinforcing its commitment to bringing next-generation medical solutions to emerging markets.About Baird Medical Baird Medical is a forward-thinking medical device company specializing in minimally invasive diagnostics and treatment. It is dedicated to the research and development of AI-powered surgical robotic systems and innovative minimally invasive surgical instruments. Our mission is to enhance patient outcomes through precision technology and advanced diagnostic solutions. The company's technological roadmap will fully integrate breakthrough innovations from the open-source AI community—leveraging cutting-edge inference models such as Deepseek and Grok3, while fostering strategic collaborations with leading academic institutions. Our vision extends beyond surgical assistance, aiming to develop intelligent systems that proactively guide diagnostic decisions and preventive healthcare strategies. As an FDA 510(k)-certified medical device company, Baird Medical has deployed its solutions in over 30 prestigious hospitals and clinics across the United States, including Johns Hopkins Hospital, Tulane Medical Center, Weill Cornell Medicine, and Columbia University Medical Center. Baird Medical is also the market leader in China in thyroid microwave ablation devices and consumables. Meanwhile, the company's minimally invasive treatment products are gradually expanding their commercial presence in over 20 countries worldwide.Forward-Looking StatementsThis press release includes certain statements that are not historical facts but are forward-looking statements for purposes of the safe harbor provisions under the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements generally relate to future events or Baird Medical's future financial or operating performance. In some cases, you can identify forward-looking statements by terminology such as "may", "could", "should", "expect", "intend", "might", "will", "estimate", "anticipate", "believe", "budget", "forecast", "intend", "plan", "potential", "predict", "potential" or "continue", or the negatives of these terms or variations of them or similar terminology. Forward-looking statements are subject to risks, uncertainties, and other factors which could cause actual results to differ materially from those expressed or implied by such forward-looking statements. These forward-looking statements are based upon estimates and assumptions that, while considered reasonable by Baird Medical and its management, are inherently uncertain. New risks and uncertainties may emerge from time to time, and it is not possible to predict all risks and uncertainties. You should not place undue reliance on forward-looking statements in this press release, which speak only as of the date they are made and are qualified in their entirety by reference to the cautionary statements herein. Baird Medical does not undertake any duty to update these forward-looking statements.Actual results may vary materially from those expressed or implied by forward-looking statements based on a number of factors, including, without limitation: (1) the risk that Baird Medical may not be successful in expanding its business in China or the United States; (2) changes in general economic conditions; (3) regulatory conditions and developments; (4) changes in applicable laws or regulations; (5) the nature, cost and outcome of pending and future litigation and other legal proceedings instituted against Baird Medical or others; and (5) other risks and uncertainties from time to time described in the Registration Statement relating to the Business Combination and the transition report, including those listed under the sections titled "Risk Factors" therein, and in ExcelFin's other filings with the SEC.The foregoing list of factors is not exclusive. Additional information concerning certain of these and other risk factors is contained in ExcelFin's most recent filings with the SEC and in the Registration Statement described above filed by Baird Medical in connection with its business combination with ExcelFin. All subsequent written and oral forward-looking statements concerning Baird Medical, the business combination described herein or other matters attributable to Baird Medical or any person acting on its behalf are expressly qualified in their entirety by the cautionary statements above. Readers are cautioned not to place undue reliance upon any forward-looking statements, which speak only as of the date made. Baird Medical expressly disclaims any obligations or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in their expectations with respect thereto or any change in events, conditions or circumstances on which any statement is based.Contact:Eric Huang, PR LiaisonBaird Medical Investment Holdings Ltd.Phone: +1 (888) 508-6228Email: [email protected]SOURCE BDMD WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In

Related News